FDA Approves New Agents for Benefit of HIV-Infected Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

ROCKVILLE, Md--In a flurry of activity at year's end, the FDA approved two new anti-HIV agents, as well as two liposomal products to combat HIV-related infections and Kaposi's sarcoma.

ROCKVILLE, Md--In a flurry of activity at year's end, the FDAapproved two new anti-HIV agents, as well as two liposomal productsto combat HIV-related infections and Kaposi's sarcoma.

Hoffmann-La Roche's saquinavir (Invirase) has become the firstprotease inhibitor to receive FDA approval. The drug has beenshown to temporarily halt the decline in CD4 counts and to increasecounts by 30 to 40 cells/mL.

Glaxo Wellcome's 3TC (lamivudine, Epivir), a reverse transcriptaseinhibitor, received approval for use in combination with AZT (zidovudine,Retrovir). The drug appears to decrease resistance to AZT andhas comparatively fewer side effects, the company said. HIV patientswho received the 3TC/AZT combination had a larger increase inCD4 cells than those on three other regimens: 3TC alone, AZT alone,or AZT plus ddC.

New Liposomal Agents

Sequus Pharmaceutical's Doxil (doxorubicin HCl liposome injection)was approved for the treatment of Kaposi's sarcoma (KS) in peoplewith AIDS whose KS disease has progressed on prior combinationchemotherapy or in patients who are intolerant to such therapy.

According to Sequus, Doxil has a circulating half-life of approximately50 hours, compared to about 10 minutes for free, nonliposome doxorubicin.This allows concentration of the encapsulated drug in areas ofthe body such as tumor where new blood vessels are forming.

The Liposome Company's Abelcet (amphotericin B lipid complex)received FDA clearance for the treatment of asper-gillosis inpatients who are refractory to or intolerant of conventional amphoteri-cinB therapy. Its use allows delivery of higher amphotericin B doseswith reduced nephrotoxicity, the company said.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content